德琪（浙江）医药科技有限公司 Deqi (zhejiang) Pharmaceutical Technology Co. LTD
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Antengene Presents Results from Three Investigational Programs at the 2024 SITC Annual Meeting 2024-11-06 09:08
Antengene to Present Results from Two Late-Stage Studies of Selinexor Signaling Potential Clinical Breakthrough at ASH 2024 2024-11-06 08:30
Antengene Announces XPOVIO® (selinexor) Approved for Its Third Indication in South Korea, Bringing Fresh Hope to Patients with MM in the Country 2024-10-18 10:35
Antengene to Present Results from Three Programs at the 2024 SITC Annual Meeting 2024-10-07 13:14
Antengene Announces XPOVIO® (selinexor) Approved for Commercialization in Thailand 2024-09-23 17:42
Antengene Announces 2024 Interim Financial Results, Highlights Progress in R&D and Commercialization 2024-08-23 12:32
Antengene Announces XPOVIO® (selinexor) Approved for Commercialization in Malaysia 2024-08-06 08:00
XPOVIO® (selinexor) Approved for New Indication in DLBCL in China, Bringing a New Treatment Option to Patients in the Country 2024-07-05 21:18
Antengene Announces XPOVIO® (selinexor) National Health Insurance Service Approval for Reimbursement in South Korea 2024-06-26 16:44
Antengene To Present One Oral and Four Abstracts at ASCO 2024 2024-05-24 08:30
Antengene Announces One Oral and Three Poster Presentations at ASCO 2024 2024-04-25 20:00
Antengene Presents Four Preclinical Posters at AACR 2024 2024-04-06 08:30
Antengene Announces Full Year 2023 Financial Results, Highlights Clinical Progress Across First-in-Class, Best-in-Class Pipeline 2024-03-22 18:00
Antengene Initiates Phase II Dose Expansion Study of Claudin 18.2 ADC ATG-022 in China and Australia 2024-03-20 20:30
Antengene Publishes Preclinical Paper on PD-L1/4-1BB Bispecific Antibody ATG-101 in Renowned Oncology Journal Cancer Research 2024-03-20 08:30
Antengene to Present Four Preclinical Abstracts at AACR 2024, Highlighting Focus on Cancer Immunology, Targeted Agents and Novel Technology Platforms 2024-03-06 08:30
Antengene Announces Inclusion of XPOVIO® (selinexor) in 2023 China's National Reimbursement Drug List 2023-12-14 09:55
Antengene Announces the Study of Anti-CD24 Monoclonal Antibody ATG-031 Dosed Its First Patient in the United States 2023-12-11 08:30
Antengene Announces XPOVIO® Regulatory Approval in Macau for the Treatment of Relapsed and/or Refractory Multiple Myeloma 2023-12-06 17:00
Antengene Presents Encouraging Clinical Data from Four Pipeline Programs at the 2023 R&D Day 2023-11-17 08:00
1 2 3 4 5 9